Updated on 19 March 2013
Prompt and effective treatment for multidrug-resistant TB requires an estimated total of $1.3 billion per year. This is where the greatest increase in funding is needed in the coming years. For 2011, funding of US$ 0.5 billion was available.
Uptake of new rapid diagnostics and associated laboratory strengthening, especially for the diagnosis of MDR-TB and for TB diagnosis among people living with HIV, requires $600 million per year. Excluding antiretroviral treatment for TB patients living with HIV, which is financed by HIV programs and their donors, about $330 million is required for HIV-associated TB interventions, such as testing TB patients for HIV, ensuring regular screening for active TB disease among people living with HIV, and providing TB preventive treatment.
In addition to the $1.6 billion annual gap in international financing for the critical implementation interventions above, WHO and partners estimate that there is a $1.3 billion annual gap for TB research and development during the period 2014-2016, including clinical trials for new TB drugs, diagnostics and vaccines.